New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021
Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment
$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential
https://finance.yahoo.com/news/adagio-therapeutics-provides-covid-19-103000746.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.